From NASDAQ.: 2025-04-29 12:24:00

Shares of Viking Therapeutics (NASDAQ: VKTX) surged 12.5% on Tuesday following positive analyst support. Cantor Fitzgerald analyst Steven Seedhouse predicts the stock could quadruple to $104 in a year due to the potential success of the VK2735 weight loss drug in phase 3 trials. Seedhouse highlights the drug’s superior formulation compared to Eli Lilly’s tirzepatide, anticipating it to become a blockbuster. However, the success of the drug remains uncertain until clinical trial data is released. The Motley Fool advises caution and diversification in investing in Viking Therapeutics.

While Viking Therapeutics shows promise, the Motley Fool Stock Advisor team has identified 10 other stocks with potential for significant returns. Joining Stock Advisor provides access to their past recommendations, which have outperformed the S&P 500 with a total average return of 872%. Consider diversifying your investments with these top stock picks.



Read more at NASDAQ.: Why Viking Therapeutics Stock Popped Again Today